NeoStem Completes Patient Enrollment in Phase 2 AMR-001 Trial

NeoStem (Nasdaq: NBS ) today announced completion of enrollment in its PreSERVE AMI study. PreSERVE AMI is a randomized, double-blind placebo-controlled Phase 2 clinical trial testing NeoStem's lead product candidate, AMR-001, an autologous adult stem cell product for the treatment of patients with left ventricular dysfunction following acute ST